The Readout Loud
396: A new trick for old science, and biotech VCs' scrambled playbook
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Why is old exon science getting new traction? What’s unsettling biotech VCs? And who will be the next CEO of PhRMA?
Adam is out, so Elaine and Allison dive into the latest news, including how China and artificial intelligence are straining biotech VC firms, in addition to more M&A. They also discuss how a cancelled Food and Drug Administration meeting led to a biotech’s demise. Plus, there’s new hope for an old theory on treating Duchenne muscular dystrophy. STAT reporter Jason Mast details the clinical testing underway.